Brought to you by 
Hexal gets rights to Labopharm's tramadol
05 May 2004
Executive Summary
Hexal AG (generics) has signed a revenue-sharing agreement with Labopharm Europe Ltd. (controlled-release drugs) in which Hexal gets German marketing and distribution rights to a once-daily formulation of the pain drug tramadol.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hexal gets rights to Labopharm's tramadol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice